Main author | Baszis | Remesal | Postępski | Simonini | Romano | Vidqvist | Pratsidou-Gertsi & Trachana | Anink | Otten | Su | Tynjälä | Klotsche |
---|---|---|---|---|---|---|---|---|---|---|---|---|
[ref] | [32] | [33] | [34] | [35] | [36] | [37] | [40] | [41] | [42] | [43] | [20] | |
n= | 136 | 26 | 39 | 135 | 27 | 19 | 13 | 18 | 39 | 30 | 27 | 209 |
% of soJIA patients in withdrawl-group | unknown | 8 | 18 | 9 | unknown | unknown | 27e | unknown | unknown | 10 | unknown | unknown |
% of soJIA patients in entire studya | 12 | NA | NA | NA | 17 | 1 | NA | 28 | 18 | NA | 6 | 6 |
Medication type | Etanercept | Etanercept | Etanercept | Etanercept | Etanercept | Etanercept | Etanercept | Etanercept | Etanercept | Etanercept | Etanercept | Etanercept |
 | Adalimumab |  |  | Adalimumab | Adalimumab | Adalimumab |  |  |  |  | Infliximab |  |
 | Infliximab |  |  | Infliximab | Infliximab | Infliximab |  |  |  |  |  |  |
 |  |  |  | d |  |  |  |  |  |  |  |  |
Time in inactive disease, months | Â | at least 6c | Â | at least 6 | at least 6 | unknown | at least 6 | unknown | unknown | at least 6 | unknown | unknown |
 mean (range) |  |  | 21.3 (4-42) |  |  |  |  |  |  |  |  |  |
 median (range) | 6.1 (0-67.9) |  |  |  |  |  |  |  |  |  |  |  |
Follow up duration, months | b | Â | Â | Â | unknown | unknown | at least 12 | Â | Â | Â | unknown | Â |
 mean (range) |  | 21 (5-44.5) | 25.4 (16-60) | 6 (3-109) |  |  |  | (10-78) | 13.4f | 26 |  | 46.8g |
% relapse after withdrawal | 68% | 69.2% | 69.2% | 75.6% | 48.1% | unknown | 84.6% | 77.8% | 38.5% | 56.7% | 55.6% | 77% |
Time to relapse, months | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 mean (range) | 5.8 (0.6-15.9) | 14.2 (1-60) |  |  | 18 (0-108) |  |  |  |  |  |  | |
 median (range) |  |  |  |  | 6.6 (2.4-28.6) |  | 3 (1-15) | 9 (1-69) |  |  |  |  |
% relapse after 3 months | 25% | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
% relapse after 6 months | 50% | 50% | 38.5% | Â | Â | Â | Â | Â | Â | Â | Â | Â |
% relapse after 12 months | 68% | 61% | Â | 68.9% | Â | Â | Â | Â | Â | Â | Â | Â |